Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Prometheus Biosciences, Inc. (Nasdaq: RXDX) has announced that Mark McKenna, Chairman and CEO, alongside Dr. Allison Luo, Chief Medical Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:45 p.m. PST. The presentation will be available for live streaming on Prometheus’ website and for 30 days afterward. The company specializes in precision medicine for immune-mediated diseases and is developing its lead candidate, PRA023, for conditions like ulcerative colitis and Crohn's disease.

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, MD, Chief Medical Officer, will present a company overview at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 3:45 p.m. PST.

The presentation will be webcast live on the Events & Webcasts page on the Investor section of Prometheus’ website and will be available for 30 days following the presentation. It is recommended that users connect to Prometheus’ website several minutes prior to the start of the webcast to ensure a timely connection.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360™, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to substantially improve outcomes for moderate-to-severe IBD patients predisposed to increased TL1A expression. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis (UC), Crohn’s Disease (CD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Prometheus Biosciences contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com

FAQ

When will Prometheus Biosciences present at the J.P. Morgan Healthcare Conference?

Prometheus Biosciences will present on January 9, 2023, at 3:45 p.m. PST.

How can I watch the Prometheus Biosciences conference presentation?

The presentation will be webcast live on Prometheus' website and available for 30 days after.

What is the main focus of Prometheus Biosciences?

Prometheus Biosciences focuses on precision medicine for the treatment of immune-mediated diseases.

What is the lead candidate for Prometheus Biosciences?

The lead candidate is PRA023, an IgG1 humanized monoclonal antibody.

What diseases is PRA023 being developed to treat?

PRA023 is being developed for ulcerative colitis, Crohn's disease, and other immune-mediated diseases.